Uncategorized

While we can at this point give no better than tossup odds to FDA plans to curtail direct-to-consumer (DTC) drug advertisements surviving inevitable legal challenges, we caution that the enforcement approach outlined by the agency…

Late Tuesday, CMS released a letter to state Medicaid offices with its preliminary interpretations of the One Big Beautiful Bill (OBBB) Act’s provision placing total payment limits on hospitals, nursing homes, and certain practitioners at…

With both chambers of Congress in session this week, talks are expected to pick up over funding the government beyond the end of the current fiscal year.  We could also see Fed nominee Stephen Miran…

We remain skeptical of Merit Medical’s (MMSI) prospects for a Medicare hospital outpatient transitional pass-through (TPT) payment for its Wrapsody Cell Impermeable Endoprosthesis (CIE), following confirmation of its application last week, setting it up for…

With last Friday’s U.S. Court of Appeals ruling against President Trump’s use of the International Emergency Economic Powers Act (IEEPA), we have the following takeaways from our trade and tariff conference call that we held…

Tuesday’s announcement by the DOJ to join a 2016 False Claims Act (FCA) whistleblower lawsuit against non-profit ProMedica Health System and its HCR ManorCare nursing homes may represent a new front in attacking long-term care…

With the House and Senate back in session this week, the focus will be on the fallout from Friday’s ruling to invalidate President Trump’s fentanyl and reciprocal tariffs, House passage of the National Defense Authorization…

We view the FY26 NIH funding bill released by the House Appropriations Committee last night, in advance of its markup at 5pm ET this afternoon, as positive for life science tools (LST) manufacturers, with both…

With the House Appropriations health subcommittee announcing a markup of its FY26 HHS funding bill on Tues., Sept. 2 [available here], we maintain our view that topline funding numbers for NIH will likely remain flat…

There are currently 9 official Section 232 investigations pending at the Department of Commerce with the furniture tariff investigation likely to become official within days, and we think more are forthcoming.  If the Trump administration…